Following a limited submission
AWMSG advice |
|||
Status: Recommended | |||
Tenofovir disoproxil (as fumarate) (Viread®) 245 mg film-coated tablets are recommended for use within NHS Wales for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis. Tenofovir disoproxil (as fumarate) (Viread®) 33 mg/g granules are recommended for use within NHS Wales for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age for whom a solid dosage form is not appropriate with: compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis. |
|||
|
|||
Medicine details |
|||
Medicine name | tenofovir disoproxil fumarate (Viread®) | ||
Formulation | 245 mg film-coated tablet, 33 mg/g granules | ||
Reference number | 1880 | ||
Indication | Treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis |
||
Company | Gilead Sciences Ltd | ||
BNF chapter | Infections | ||
Submission type | Limited | ||
Status | Recommended | ||
Advice number | 2313 | ||
NMG meeting date | 19/06/2013 | ||
AWMSG meeting date | 17/07/2013 | ||
Ratification by Welsh Government | 14/08/2013 | ||
Date of issue | 15/08/2013 | ||
Date of last review | December 2022 | ||
Further information This appraisal recommendation was reviewed in December 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |